

Re: World Health Summit 2012, Berlin October 21st - 24th 2012

From: Presidents Prof. Steve Wesselingh, Melbourne, Prof. Mike Klag, Baltimore, and Prof. Detlev Ganten, Berlin

The World Health Summit, Berlin October 23rd to 26th, 2011 - under the theme "Today's Science – Tomorrow's Agenda" - provided a wealth of information, interesting debates, inspiring presentations and stimulating new developments. In addition, the summit created an excellent forum for informal discussions and new connections. The Key Messages (www.worldhealthsummit.org) provide you with the main results of the discussions, showing that important steps in improving health worldwide have been taken, but that many new challenges, e.g. the rapid increase of Non-Communicable Diseases and the impact of Climate Change on Health, need to remain on the agenda!

- Non-communicable diseases (NCD) are now the leading cause of death worldwide. The great public health burden of treating rising numbers of chronically ill patients, including obesity, diabetes, cardiovascular diseases and mental illnesses, will become increasingly unacceptable. Awareness must be raised about the global economic risk and impact of chronic/NCDs.
- Climate change is already having significant impact on the human health. It will pose a fundamental threat to human biological and social wellbeing. Societies worldwide need to adapt in order to reduce the projected adverse impacts ranging from new epidemics of infectious diseases to altered agriculture and nutrition. Strengthening national and international public health infrastructure is an essential component in the management of floods, other extreme weather events and health emergencies.
- Strengthening health systems and the transformation of "sick care" to true "health care" systems and research for prevention of disease are important drivers for sustainable economic, social and human development, not only in low- and middle-income countries. If the scale of investments in global health is not maintained, worldwide improvements previously achieved at great cost are at risk. It is crucial for long-term sustainability that countries in general and especially in the developing world do not respond with major cuts in research and health care spending in these times of global financial crisis.
- Academia, governments, industry and civil society must jointly develop sustainable solutions in a truly global and multi-disciplinary approach. Innovative ways of maximizing the benefits from limited resources must be developed to ensure that the gains from medical progress reach as many people as possible.

We have the responsibility that innovation is brought to the people in need. The "M8 Alliance of Academic Health Centers and Medical Universities" has therefore chosen the theme for the next World Health Summit 2012, October 21st to 24thin Berlin to be: "Research and Innovation – in times of global financial crisis". Join us next year in Berlin and stay informed by visiting our website www.worldhealthsummit.org

Steve Wesselingh

Mike Klag

Michael g. Klag.

Detlev Ganten



Summit Profile



Our Vision

To improve health worldwide by strengthening the links between research, academic medicine, the private sector, civil society, politics and all other healthcare stakeholders.

- The **World Health Summit** is a joint initiative by the "M8 Alliance of Academic Health Centers and Medical Universities", launched in 2009 in partnership with the major international organizations in research and health around the world.
- The **World Health Summit** intends to reframe the global debate on research and health by bringing together multisectoral representation from academia, politics, industry, media and the civil society, in an inspiring setting, to engage in creative interactions.
- The **World Health Summit** aims at highlighting gaps between scientific evidence, policy and practice by tapping on testimonies from scientists and actors in the various fields of health and infusing policy formulation and new solutions with ground reality.

"The theme "Today's Science – Tomorrow's Agenda", is timely and befitting as we explore policy approaches to respond to emerging health challenges...I would like to applaud Dr. Angela Merkel for her untiring efforts to entrench health issues in the global discourse."

Sheikh Hasina, Prime Minister of Bangladesh, October 2011

Participant Profile



- Top-level researchers and members of the scientific community
- High-profile political decision-makers
- Executives and representatives from the health care system
- Leaders of the health-related industry and technology sector
- Representatives of civil societies and foundations
- Students and young professionals from all health related fields

"Berlin has now secured its place on the global health calendar...last weeks meeting succeeded in being more cosmopolitan than ever before."

Summit Presidents



Founding President

Detley Ganten

Charité – Universitätsmedizin Berlin, Germany

President 2012

Michael J. Klag

Johns Hopkins Bloomberg School of Public Health,

Baltimore, USA

Past Presidents

Axel Kahn, 2009

Université Paris Descartes,

France

Steven Smith, 2010

Imperial College London, UK

Steve Wesselingh, 2011

Monash University, Australia

"The World Health Summit has become the foremost global meeting of its kind to convene leaders from academia, economy, industry, governments, international organizations and civil society around the pressing health issues of our time."

Nicolas Sarkozy, President of the French Republic

"The recently launched World Health Summit offers a rare chance for dialogue."

Nature, Vol. 462, November 2009

Steering Board and Council



Steering Board

Jean-François Girard

President PRES Sorbonne Paris Cité, France

Richard Horton
Editor-in-Chief, The Lancet, United Kingdom

Sabine Kleinert Senior Executive Editor, The Lancet, United Kingdom

Peter Piot
Director, London School of Hygiene & Tropical
Medicine, United Kingdom

Ernst Rietschel Former President Leibniz Association, Germany

John Wong
Dean, Yong Loo Lin School of Medicine, National
University of Singapore, Singapore

Elias Zerhouni Head of Research and Development, Sanofi, France

Council

Ala Alwan
Rifat Atun
Christopher Baethge
Andreas Barner
Zulfiqar Bhutta
James Chau
Pierre Corvol
Klaus Dugi
David de Kretser
Guy de Thé

Jean Francois Dupuis

Tim Evans

Richard Feachem Antoine Flahault

Tedros Adhanom Ghebreyesus

Louise Gunning-Schepers

Jörg Hacker
Andy Haines
Stefan Kaufmann
Ilona Kickbusch
Dirk Kosche
Eduardo Krieger
Philippe Meyer
Joel Menard

Tikki Pang
Vikram Patel
Andreas Penk
Wolfgang Plischke
Olivier Raynaud
Erich R. Reinhardt
Heinz Riederer
Mary Robinson

Hans-Joachim Schellnhuber

Günter Stock
Timo Ulrichs
Cesar G. Victora
Sonja Weinreich
Reinhard Wichels
Vera Zylka-Menhorn

Speakers at previous summits



- Roselyne Bachelot, (Former) Minister of Health, France
- Francoise Barré-Sinoussi, Nobel Prize Laureate in Medicine 2008
- Gilbert Bukenya, Vice President of the Republic of Uganda
- Mickey Chopra, Chief of Health, UNICEF
- Sheikh Hasina, Prime Minister of Bangladesh
- Richard Horton, Editor-in-Chief, The Lancet
- Tedros A. Ghebreyesus, Federal Minister of Health, Ethiopia
- Zsuzsanna Jakab, Director, European Regional Office, WHO
- Joe Jiminez, CEO, Novartis AG
- Unni Karunakara, International President, Médicins sans

Frontières

- Michel Kazatchkine, Executive Director, The Global Fund
- Tomica Milosavljevic, Minister of Health, Serbia
- Luc Montagnier, Nobel Prize Laureate in Medicine 2008
- Aaron Motsoaledi, Minister of Health, South Africa
- Wolfgang Plischke, Chairman of the Board, Bayer AG

• Michael Rawlins, Chairman, National Institute for Health and Clinical

Excellence (NICE), UK

- Philipp Rösler, Former Federal Minister of Health, Germany
- Hermann Requardt, CEO Healthcare, Siemens
- Mary Robinson, Former President of the Republic of Ireland, Chair of the GAVI Board
- Jorge Sampaio, Former President of Portugal
- John Sulston, Nobel Prize Laureate in Medicine 2002
- Annette Schavan, Federal Minister of Education and Research,
 Germany
- Hans-Joachim Schellnhuber, Director, *Potsdam Institute for Climate Impact Research, Germany*
- Oumar I. Touré, Minister of Health, Mali
- Christopher A. Viehbacher, CEO, Sanofi-Aventis
- Marc Walport, Director, The Wellcome Trust
- Ada E. Yonath, Nobel Prize Laureate in Chemistry 2009
- Harald zur Hausen, Nobel Prize Laureate in Medicine 2008

World Health Summit 2012



Key Facts

Date

October 21st - 24th, 2012

Venue

Langenbeck-Virchow-Haus Luisenstrasse 58/59 10117 Berlin, Germany

Number of participants 1400

For more information

- www.worldhealthsummit.org
- Sign up for the World Health Summit Newsletter: www.worldhealthsummit.org/newsletter/





Contacts

Academic Office

Charité – Universitätsmedizin Berlin PD Dr. Mazda Adli, Executive Director Mazda.Adli@charite.de Dr. Mathias Bonk, Program Coordinator Mathias.Bonk@charite.de

Organizing Office

K.I.T. Group Association & Conference Management Sophie Spangenberger, Organizing Manager secretariat@worldhealthsummit.org

M8 Alliance – International Network




- The "M8 Alliance of Academic Health Centers and Medical Universities" was officially founded in 2009, on the occasion of the 1st World Health Summit as a medical and scientific forum of excellence.
- It is composed of a network of prestigious medical institutions dealing with scientific, political, and economic issues related to medicine and global health, together with stakeholders from politics, society, non-governmental institutions and industry worldwide.
- This international network gives the World Health Summit an outstanding academic background. The M8 Alliance acts as a permanent platform for framing future considerations of global medical development and health challenges.
- It is the M8's vision to harness academic excellence to improve global health.

"The World Health Summit of the M8 Alliance is for medicine and health what the World Economic Forum in Davos is for the economy. It should grow towards a strong tradition and an essential motor for health research."

Annette Schavan, German Federal Minister of Education and Research

M8 Alliance – International Network





M8 Alliance – International Network





MCMS or from other sources, would have been feasible and informative. With no such analysis, extrapolation of these findings to other settings is difficult.

Although the investigators report strong associations between neonatal mortality and place of birth (home vs hospital), such inferences are based on a cross-sectional analysis of the 2002–08 MCMS data that did not take account of important covariates. Many characteristics differentiate families that choose (or have access to) facility deliveries and those who deliver at home; such differences would be expected to exist within, and not just between, sociodemographic categories. The lack of statistical adjustment for key confounders suggests that the estimates of preventable fractions should be cautiously interpreted.

Finally and importantly, we acknowledge the concerns about quality of the data from China's MCMS, on which Feng and colleagues base their conclusions. Although the MCMS is a rich source of demographic data, it has been criticised for systematically under-reporting births and deaths and for the large variation in the distribution of surveillance sites in the past two decades. Also Inaccurate estimation of the number of births might have biased the analyses. For example, if home births were less likely to be reported than hospital births, home-birth mortality rates could be spuriously inflated. Additionally, increases in the completeness of birth reporting over time could result in apparent declines in neonatal mortality rates.

Provision of high-quality facility-based obstetric and neonatal care will undoubtedly improve neonatal survival, and Feng and colleagues indicate how this improvement might have developed in China during the past 15 years. Nevertheless, a more complete assessment of the effect of China's national policy to promote institutional deliveries on neonatal mortality rate is warranted. We look forward to further studies based on MCMS data, especially with creative

combinations of information from many sources¹¹ and analyses aimed at untangling the complex effects of policies and interventions on maternal and child health. Studies using China's abundant epidemiological and demographic data, and the uniqueness of its nationwide policy experiences, could offer invaluable contributions to worldwide public health knowledge.

*Diego G Bassani, Daniel E Roth Department of Paediatrics, Hospital for Sick Children, and University of Toronto, Toronto, ON, Canada M5G 1X8 diego.bassani@sickkids.ca

We thank Robert Black and Zulfiqar Bhutta for their comments and suggestions. We declare that we have no conflicts of interest.

- Bhutta ZA, Chopra M, Axelson H, et al. Countdown to 2015 decade report (2000–10): taking stock of maternal, newborn, and child survival. Lancet 2010; 375: 2032–44.
- Oestergaard MZ, Inoue M, Yoshida S, et al, for the United Nations Inter-agency Group for Child Mortality Estimation and the Child Health Epidemiology Reference Group. Neonatal mortality levels for 193 countries in 2009 with trends since 1990: a systematic analysis of progress, projections, and priorities. PLoS Med 2011; 8: e1001080.
- 3 Black RE, Cousens S, Johnson HL, et al, for the Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375: 1969-87.
- 4 Wall SN, Lee AC, Carlo W, et al. Reducing intrapartum-related neonatal deaths in low-and middle-income countries—what works? Semin Perinato 2010; 34: 395-407.
- 5 Kumar V, Kumar A, Darmstadt GL. Behavior change for newborn survival in resource-poor community settings: bridging the gap between evidence and impact. Semin Perinatol 2010; 34: 446–61.
- 6 Victora CG, Barreto ML, do Carmo Leal M, et al, for the Lancet Brazil Series Working Group. Health conditions and health-policy innovations in Brazil: the way forward. Lancet 2011; 377: 2042–53.
- 7 Rajaratnam JK, Marcus JR, Flaxman AD, et al. Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970–2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet 2010; 375: 1988–2008.
- 8 Rudan I, Chan KY, Zhang JS, et al, for WHO/UNICEF's Child Health Epidemiology Reference Group (CHERG). Causes of deaths in children younger than 5 years in China in 2008. Lancet 2010; 375: 1083–89.
- 9 Feng XL, Guo S, Hipgrave D, et al. China's facility-based birth strategy and neonatal mortality: a population-based epidemiological study. *Lancet* 2011; published online Sept 16. DOI:10.1016/S0140-6736(11)61096-9.
- 10 Gao Y, Kildea S, Barclay L, Hao M, Zeng W. Maternal mortality surveillance in an inland Chinese province. Int J Gynaecol Obstet 2009; 104: 128–31.
- Victora CG, Black RE, Boerma JT, Bryce J. Measuring impact in the Millennium Development Goal era and beyond: a new approach to large-scale effectiveness evaluations. Lancet 2011; 377: 85–95.

Science to policy: M8 Alliance invites policy makers to step in

A year ago, we introduced the M8 Alliance and called for academic medicine to take more responsibility for global health. The M8 Alliance connects leading medical universities and national academies worldwide to create a network that actively seeks dialogue with governmental representatives, policy makers, nongovernmental organisations, civil society, and health-related industry on specific global health challenges.¹

On some aims we have had progress, for example on the effects of global warming on health, a topic that is still neglected at our peril. Initiated by the M8 Alliance and through discussions at the World Health Summit



See Perspectives page 1455

in 2010, the Interacademy Medical Panel (IAMP)—the organisation of 65 national academies of medical science—presented a statement on the health threats of climate change. The IAMP made a number of recommendations that emphasise the health cobenefits of policies to mitigate climate change for the UN climate change talks in Cancun, Mexico, in November, 2010.² A first important step, but much more needs to be done to engage governmental representatives and other policy makers and to provide scientific evidence to focus their attention on urgent health issues with long-term consequences.

The M8 Alliance does not sufficiently involve academic institutions from low-income and middle-income countries where societal transition and demographic change alter their population's health burden.3 These countries, in particular, are looking for the development of cost-effective interventions and low-cost health infrastructure.4 It is therefore an important development that this year Brazil and Singapore have joined the M8 Alliance through the University of São Paulo and the National University of Singapore. Both countries represent outstanding examples of the effects of national policies that put significant emphasis on health.^{5,6} The M8 Alliance has begun to hold regional meetings in 2011; these are held in the particular year's co-hosting country (2011 Melbourne, Australia; 2012 Baltimore, USA; and 2013 Singapore) and focus on topics of relevance for the hosting region.

The M8 Alliance continues in its aim to provide the scientific sources for evidence-based policy. Four key aims are currently a focus for the group's attention and activities: mental wellbeing in large urban areas and megacities, reduction of risk factors for non-communicable diseases, the health impacts of climate change, and research and workforce capacity building in low-income and middle-income countries.

Urbanisation progresses at a rapid pace, bringing new and different challenges. Three quarters of the world's megacities of 10 million or more people, such as Mexico City, Mexico, São Paulo, Brazil, or Mumbai, India, are in middle-income countries. By 2050, 70% of the world's population will live in urban areas. Insufficient security, lack of private space, and inadequate housing conditions are among the social stressors that are associated with an increased stress vulnerability and a higher risk for mental disorders in urban dwellers.

Societal transition is leading to rapid demographic changes, especially in middle-income and low-income countries, that result in higher life expectancies but also in an increase of chronic diseases without adequate prevention capacities. Epidemiological projections show an increase of 80% for diabetes in Africa between 2006 and 2025, compared with the predicted worldwide increase of 55%. Processed food, high in fats, salt, and sugar, fuels the obesity epidemic, which has become one of the major health threats in countries like Mexico and Brazil.

In September, the UN General Assembly gathered to discuss actions on non-communicable diseases. The political declaration agreed at the meeting is an appreciated first step, ¹⁰ but there is still a long way to go. Science must inform policy, especially under conditions of financial constraints when investments need to be directed towards the most cost-effective and evidence-based action plans and preventive measures.

Governments must integrate health into their political agendas, as their population's health is their most important economic asset. Politicians need to align with academia to identify the scientific evidence and arguments to determine the best strategies to choose from. It is an important and encouraging development that governmental authorities now show an increasing engagement in the World Health Summit, using this conference as a leading forum for exchange with the different stakeholder groups involved in the complex field of global and national health. Governmental authorities from more than 30 countries from all global regions are involved in this year's World Health Summit; the German Federal Government contributes with four Ministries (Education and Research, Health, Foreign Affairs, and Economic Cooperation and Development) to the conference. Interdepartmental linkages are key to assess and tackle complex health issues such as ageing populations, obesity, and cancer.

The World Health Summit 2011 in Berlin, Germany, is a unique occasion for policy makers to discuss urgent health issues with experts from all sectors with clear linkages to health, like science, the economy, and foreign policy. The door is open, and it is now up to policy makers to step in. An increasing involvement of governments of the M8 countries and beyond in the World Health Summit and the M8 process will be an important marker for success in the initiative's future.

For **World Health Summit** see http://www.worldhealth summit.org *Mazda Adli, Sabine Kleinert, Mathias Bonk, Steve Wesselingh, Detlev Ganten Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany (MA, MB, DG); The Lancet, London, UK (SK); and Monash University, Faculty of Medicine, Nursing and Health Sciences, Victoria, Australia (SW) mazda.adli@charite.de

MA is Executive Director, MB is Programme Coordinator, DG is Founding President. and SW is Co-President of the World Health Summit 2011.

- Adli M, Kleinert S, Smith SK, Ganten D. Academic medicine must take its global role: the M8 Alliance of Academic Health Centers and Medical Universities. Lancet 2010; 376: 1197–98.
- 2 Ganten D, Haines A, Souhami R. Health co-benefits of policies to tackle climate change. *Lancet* 2010; 376: 1802–04.

- 3 Bloom DE, Cafiero ET, Jané-Llopis E, et al. The global economic burden of non-communicable diseases. Geneva: World Economic Forum, 2011.
- 4 Crisp N. Turning the world upside down: the search for global health in the 21st century. London: The Royal Society of Medicine Press, 2010.
- Victora CG, Barreto ML, do Carmo Leal M, et al. Health conditions and health-policy innovations in Brazil: the way forward. Lancet 2011; 377: 2042–53.
- 6 Lim MK. Transforming Singapore health care: public-private partnership. Ann Acad Med Singapore 2005; 34: 461–67.
- 7 Dye C. Health and urban living. Science 2008; 319: 766-69.
- 8 Peen J, Schoevers RA, Beekman AT, Dekker J. The current status of urban-rural differences in psychiatric disorders. Acta Psychiatr Scand 2009; 121: 84–93.
- 9 Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. Heart 2008; 94: 1376–82.
- 10 Beaglehole R, Bonita R, Alleyne G, Horton R. NCDs: celebrating success, moving forward. Lancet 2011; 378: 1283–84.

Time for zero deaths from tuberculosis

When Robert Koch presented his discovery of the tuberculosis bacillus in March, 1882, he hoped it would lead to the eradication of "this terrible plaque of mankind".1 More than a century later, tuberculosis remains a leading killer of adults: of about 9.4 million people newly infected with tuberculosis each year, 3.5 million are undiagnosed and continue to transmit the disease and more than 1.7 million die. Tuberculosis is the main killer of people with HIV infection; drug-resistant strains continue to spread; and paediatric tuberculosis remains an area of neglect.^{2,3} In the past decade, the number of new cases of tuberculosis worldwide has barely declined, and the number of deaths remains catastrophic: more than 4500 per day for this largely treatable disease. As a Lancet editorial pointed out, "A status quo in tuberculosis control is unacceptable."4

This status quo is not inevitable. A logical place to look for fresh leadership and vision is the Stop TB Partnership. Created in 2001 as a network of international organisations, countries, technical agencies, and donors, the Partnership was tasked with ensuring that every patient with tuberculosis has access to effective diagnosis and treatment. In its first decade, however, the Stop TB Partnership—housed at WHO headquarters in Geneva—seems to have operated essentially as a subsidiary of WHO's Tuberculosis Department with the majority of funds going to WHO's Tuberculosis Department, rather than external partners. ^{5,6} But this situation may yet change. The newly appointed Executive Secretary of the Partnership, Lucica Ditiu, has initiated steps to address potential financial and administrative conflicts

of interest in the Stop TB Partnership's relation with WHO. More importantly, Ditiu has called for a bold new vision in the struggle against tuberculosis. She and her team have started a campaign to prevent a million deaths among patients co-infected with HIV and tuberculosis.⁷ She should be congratulated for these steps and supported in her efforts by her Board, the WHO Director-General, governments of countries with a high-burden of tuberculosis, and the tuberculosis community. Transforming the Partnership into an effective, independent, and transparent body capable of acting as a locus for innovative thinking is a crucial step in recasting the global struggle against tuberculosis.

Changing the tenor of advocacy around tuberculosis is another important step. Without the networks of grassroots health activists and civil society institutions that define the HIV/AIDS movement, the global tuberculosis community has been unable to successfully scale-up patient-centred approaches to care, or hold governments and key international bodies (including funders) to account with regard to their commitments to tackle this disease. The health-activist community must take urgent steps to remedy this. Investment in tuberculosis-specific efforts of existing HIV/AIDS and civil society organisations—building on such efforts in Brazil, Kenya, India, South Africa, Uganda, and Zambia—or groups working on related social issues would be a start.

Much would be achieved if leaders of global health initiatives—the Global Fund to Fight AIDS, Tuberculosis and Malaria, the US President's Emergency Plan For AIDS Relief, the US Global Health Initiative, and



See Editorial page 1439
See Perspectives page 1456

For a **profile of Lucica Ditiu** see **Perspectives** *Lancet* 2011; **377:** 1067